08/28/2025 | Press release | Distributed by Public on 08/28/2025 20:12
PITTSBURG - U.S. Senator Maggie Hassan, a senior member of the Senate Homeland Security Committee, recently received a security briefing from U.S. Customs and Border Protection (CBP) and members of state and local law enforcement on the evolving threats in the Swanton Sector of the Northern border. The Swanton Sector covers portions of the U.S.-Canada border in New Hampshire, Vermont, and New York. Following the briefing, Senator Hassan accompanied CBP officers to tour a segment of the border and meet with a constituent to discuss security concerns.
"I appreciated the opportunity to meet with Border Patrol and state and local law enforcement leaders and tour a segment of our Northern border with them. Strengthening security at our borders is an important part of our efforts to combat fentanyl and our overall national security," said Senator Hassan. "I am grateful for the work that our law enforcement officers are doing to keep our communities safe, and I will keep working to support their efforts to strengthen security at both our Northern and Southern borders."
This visit is part of Senator Hassan's ongoing efforts to strengthen border security. Senator Hassan has visited both the Northern and Southern borders several times as a member of the Senate Homeland Security Committee. Last month, the Senate Homeland Security Committee advanced bipartisan legislation introduced by Senator Hassan to strengthen security at the Northern border by requiring the Department of Homeland Security to regularly complete a new Northern Border Threat Analysis and update its Northern Border Strategy. Last year, Senator Hassan worked with her colleagues to pass into law the END FENTANYL Act, which requires Customs and Border Protection to keep its policies to stop and interdict drugs up-to-date. Additionally, Senator Hassan helped introduce the bipartisan HALT Fentanyl Act, which was signed into law last month and permanently classifies all fentanyl-related substances as Schedule I drugs under the Controlled Substances Act.
###